News

FA Europe Meeting Unites Physicians, Researchers and Advocates in Paris

On May 24th, 2024, the FA Europe Network hosted its inaugural pan-European scientific meeting at the historic Saint-Louis Hospital in Paris, marking a significant milestone in international collaboration for Fanconi anemia (FA).

Read More >

Behind the Research: Andrew Deans

My lab’s vision for the next five years is to apply what we have learned to develop molecules that can alter FA protein behavior. These could be used to treat cancer or alter gene editing outcomes.

Read More >

Inspiration Through Education: Omar’s Journey with Fanconi Anemia

In a world where every day presents new challenges, my 11-year-old son, Omar, from Oman, stands out for his resilience and eagerness to raise awareness about Fanconi anemia. Diagnosed at just five years old, we truly believe his journey is a testament to hope and the strength of the human spirit.

Read More >

Breaking Ground in Cancer Research: Introducing the Fanconi Cancer Foundation-AACR NextGen Grant

That's why we're thrilled to announce the launch of the Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity in partnership with the American Association for Cancer Research (AACR).

Read More >

Introducing the Fanconi Cancer Foundation: A New Era in FA Research & Impact

In 1989, Lynn and David Frohnmayer founded the Fanconi Anemia Research Fund (FARF), determined and desperate to find a cure for their three daughters diagnosed with Fanconi anemia (FA). Since then, their vision has grown into a vibrant community of FA families, researchers, clinicians, donors, fundraisers, staff, and volunteers, all dedicated to improving outcomes for people with FA.

Read More >

2025 Research Updates

Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.

Read More >